Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in request metadata) on February 4, 2009. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates rather than financial performance.
Material Changes
The material event reported is the issuance of a press release providing an update on two-year survival data from an ongoing Phase 1/2 clinical trial of the company's drug candidate, OGX-011, in patients with Non-Small Cell Lung Cancer.
Guidance, Outlook, and Risks
- Management Commentary: The company provided an update on clinical trial data but did not include specific financial guidance or forward-looking projections in this filing.
- Legal Status: The information contained in this report and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific two-year survival data percentages and patient cohort details in the attached press release (Exhibit 99.1).
- Confirm the current status of the Phase 1/2 clinical trial for OGX-011.
- Review subsequent filings for any financial impact resulting from the clinical trial outcomes.